Data

Medication Elimination

Hallberg SJ, McKenzie AL, Williams P, et al. Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at One Year: An Open Label, Non-Randomized, Controlled Study. Diabetes Ther. 2018. DOI: 10.1007/s13300-018-0373-9

Drug Class Percent of Prescriptions Eliminated
Sulfonylureas 100.0%
SGLT-2 91.3%
Thiazolidinedione 80.0%
DPP-4 54.8%
Insulin 47.6%
GLP-1 28.6%
Metformin 18.6%

A1c Reduction

Hallberg SJ, McKenzie AL, Williams P, et al. Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at One Year: An Open Label, Non-Randomized, Controlled Study. Diabetes Ther. 2018. DOI: 10.1007/s13300-018-0373-9

Baseline 10 weeks 1 year
Virta 7.5 6.4 6.2
Usual Care 7.7   7.9

Weight Reduction

Hallberg SJ, McKenzie AL, Williams P, et al. Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at One Year: An Open Label, Non-Randomized, Controlled Study. Diabetes Ther. 2018. DOI: 10.1007/s13300-018-0373-9

Treatment Weight loss at 12 months
Virta 12%

Retention

Bar chart comparing retention at one year: Virta (90%), Diabetes Medication Adherence (48%), Weight Loss Programs (13%)

Virta Health Registry for Remote Care of Chronic Conditions. Health and economic outcomes as of March 2019

Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016;10:1299–1307. Published 2016 Jul 22. doi:10.2147/PPA.S106821

Martin CK, Talamini L, Johnson A, Hymel AM, Khavjou O. Weight loss and retention in a commercial weight-loss program and the effect of corporate partnership. Int J Obes (Lond). 2010;34(4):742–750. doi:10.1038/ijo.2009.276

Treatment Retention
Virta 90%
Diabetes Medication Adherence 48%
Weight Loss Programs 13%

Rx Reduction

Line chart showing Rx Reduction over 2 years

Athinarayanan SJ, Adams RN, Hallberg SJ, et al. Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-year Non-randomized Clinical Trial. Frontiers in Endocrinology. 2019; 10:348. DOI: 10.3389/fendo.2019.00348

Time in Clinic Diabetes-specific prescription use compared to baseline (%)
Baseline 100
10 weeks 42.5
6 months 41.9
1 year 41.9
2 years 40.2

Type 2 Diabetes

Bar charts showing comparison of Virta to Usual Care: Type 2 diabetes medications

Hallberg SJ et al. Diabetes Therapy. 2018;9(2):583-612 and Bhanpuri NH et al. Cardiovasc Diabetol. 2018; 17:56.

Mean percent change after one year
Metric Virta Usual Care
Hemoglobin A1c -17.24 2.62
Fasting glucose (mg·dL-1) -21.83 7.23
Insulin, all (mU·mL-1) -36.83 2.95
HOMA-IR (insulin derived), excluding exogenous insulin users -54.87 16.06
Any diabetes medication, excluding metformin (%) -47.81 8.98

Obesity

Bar chart showing comparison of Virta to Usual Care: Weight loss

Hallberg SJ et al. Diabetes Therapy. 2018;9(2):583-612 and Bhanpuri NH et al. Cardiovasc Diabetol. 2018; 17:56.

Mean percent change after one year
Metric Virta Usual Care
Weight-clinic (kg) -11.84 -0.15

Atherogenic Dyslipidemia

Bar charts showing comparison of Virta to Usual Care: Atherogenic Dyslipidemia

Hallberg SJ et al. Diabetes Therapy. 2018;9(2):583-612 and Bhanpuri NH et al. Cardiovasc Diabetol. 2018; 17:56.

Mean percent change after one year
Metric Virta Usual Care
Triglycerides (mg·dL-1) -24.39 10.19
HDL-C (mg·dL-1) 18.10 -2.83

Hypertension

Bar charts showing comparison of Virta to Usual Care: Hypertension

Hallberg SJ et al. Diabetes Therapy. 2018;9(2):583-612 and Bhanpuri NH et al. Cardiovasc Diabetol. 2018; 17:56.

Mean percent change after one year
Metric Virta Usual Care
Systolic blood pressure (mmHg) -4.82 -0.69
Diastolic blood pressure (mmHg) -4.28 -1.10
Any blood pressure medication (%) -17.01 15.72

Inflammation

Bar charts showing comparison of Virta to Usual Care: Inflammation

Hallberg SJ et al. Diabetes Therapy. 2018;9(2):583-612 and Bhanpuri NH et al. Cardiovasc Diabetol. 2018; 17:56.

Mean percent change after one year
Metric Virta Usual Care
hsC-reactive protein (mg·L-1) -39.34 14.77
WBC (k·mm-3) -9.10 -0.74

Safety

Bar charts showing comparison of Virta to Usual Care: Safety measures

Hallberg SJ et al. Diabetes Therapy. 2018;9(2):583-612 and Bhanpuri NH et al. Cardiovasc Diabetol. 2018; 17:56.

Mean percent change after one year
Metric Virta Usual Care
Anion gap (mmol·L-1) 4.24 11.83
Uric acid (mg·dL-1) 0.68 -3.56
Serum creatinine (mg·dL-1) -4.55 -2.20
ALT (µkat·L-1) -29.82 2.02
AST (µkat·L-1) -20.61 3.01

Cardiovascular Risk Markers

Bar charts showing comparison of Virta to Usual Care: Cardiovascular risk markers

Hallberg SJ et al. Diabetes Therapy. 2018;9(2):583-612 and Bhanpuri NH et al. Cardiovasc Diabetol. 2018; 17:56.

Mean percent change after one year
Metric Virta Usual Care
10-year ASCVD risk -11.93 11.21
Total LDL-P (nmol·L-1) -4.89 -4.41
Small LDL-P (nmol·L-1) -20.76 2.53
LDL-C (mg·dL-1) 9.62 -10.91
ApoB (mg·dL-1) -1.62 0.25
ApoB/ApoA1 ratio -9.46 1.37